Regulus Therapeutics Newsroom

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

newsfilter.ioAug 28 20:00

Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target

BenzingaAug 15 01:36 · Ratings

Buy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal Trial

TipRanksAug 9 20:10 · Ratings

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

BenzingaAug 9 05:34

Express News | Regulus Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $95.9 Mln; Cash Runway Into H1 2026

BreakingsAug 9 04:43

Regulus Therapeutics | 10-Q: Q2 2024 Earnings Report

SECAug 9 04:30 · Announcements

Express News | Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

BreakingsAug 9 04:05

Express News | Regulus Therapeutics Q2 Operating Expenses USD 12.26 Million

BreakingsAug 9 04:05

Express News | Regulus Therapeutics Q2 Net Income USD -11.036 Million

BreakingsAug 9 04:05

Express News | Regulus Therapeutics Q2 Basic EPS USD -0.17

BreakingsAug 9 04:05

Express News | Regulus Therapeutics Q2 Pretax Profit USD -11.035 Million

BreakingsAug 9 04:05

Express News | Regulus Therapeutics Q2 Income From Operations USD -12.26 Million

BreakingsAug 9 04:05

Regulus Therapeutics 2Q Loss/Shr 17c >RGLS

Dow JonesAug 9 04:05

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Yahoo FinanceAug 6 20:00

Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7

Oppenheimer analyst Andreas Argyrides maintains $Regulus Therapeutics(RGLS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 45

Futu NewsAug 2 20:35 · Ratings

Express News | Regulus Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $7

BreakingsAug 2 20:22

Oppenheimer Initiates Regulus Therapeutics at Outperform With $7 Price Target

MT NewswiresAug 2 19:38 · Ratings

Oppenheimer Initiates Regulus Therapeutics(RGLS.US) With Buy Rating, Announces Target Price $7

Oppenheimer analyst Andreas Argyrides initiates coverage on $Regulus Therapeutics(RGLS.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success

Futu NewsAug 2 05:32 · Ratings

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

BenzingaJul 16 20:11

H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10

H.C. Wainwright analyst Ram Selvaraju maintains $Regulus Therapeutics(RGLS.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 4

Futu NewsJul 16 18:31 · Ratings